StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MBRXBearishIndustry Newsnews
High materiality7/10

Moleculin's Annamycin shows AML remission signals; trial to proceed

Jun 30, 2026, 2:21 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Near-term price pressure from interim data lacking statistical significance and a sizable pre-release drop; potential rebound if final readout is positive. This pattern mirrors biotech moves where interim data trigger volatility but final results drive long-term valuation.

AI summary

What happened, with direct paths to the underlying reporting

New MIRACLE trial data show Annamycin arms achieved higher CRc after one cycle (50% and 57%) versus 29% control in relapsed/refractory AML. The Independent Data Monitoring Committee recommended keeping both doses and continuing the trial, with significance expected only at the final analysis under the O’Brien-Fleming design. Moleculin Biotech stock dropped about 26% on the news.

  • Annamycin arms show higher remission than control after one cycle in MIRACLE; IMC recommends continuing.
  • CRc 50% and 57% in Annamycin arms vs 29% control.
  • Remissions reflect a single cycle per MIRACLE protocol.
  • First 45 patients: 75.6% over 60; 55.6% had 7+3; 31.1% venetoclax-first-line.
  • MBRX stock fell ~25.7% to $3.02 on the news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event